Endothelin in hypertension: An update

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 128-136

  Rautureau, Yohann ^a   Schiffrin, Ernesto L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

clinical trials; contractility; endothelium; ET A receptors; genetically modified mice; signalling; vascular gene expression; vascular smooth muscle cells

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; APOLIPOPROTEIN E; ATRASENTAN; BOSENTAN; BQ 610; CALCITONIN GENE RELATED PEPTIDE; CALCIUM ION; CONTRACTILE PROTEIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IPI 725; L 744453; L 751281; L 754142; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; RES 7011; RO 468443; SITAXSENTAN; STROMAL INTERACTION MOLECULE 1; TAK 044; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL WALL; CLINICAL TRIAL (TOPIC); ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; FLUID RETENTION; FOOT EDEMA; GENE EXPRESSION; GENETIC MODEL; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; LIPID DIET; LIPID METABOLISM; MUSCLE CONTRACTION; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROCESSING; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR BIOLOGY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; ENDOTHELIN-1; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

EID: 84857051755     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834f0092     Document Type: Review

References (75)

1. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603. (Pubitemid 47247855)
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415. (Pubitemid 18090241)
3. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300. (Pubitemid 23065167)
4. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-188. (Pubitemid 24239426)
5. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1- mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-736.
6. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86:485-498.
7. Khimji AK, Rockey DC. Endothelin: Biology and disease. Cell Signal 2010; 22:1615-1625.
8. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011; 91:1-77. Excellent extensive review on the endothelin system.
9. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005; 43:19-29. (Pubitemid 40828829)
10. Iglarz M, Clozel M. At the heart of tissue: Endothelin system and end-organ damage. Clin Sci (Lond) 2010; 119:453-463.
11. Lattig J, Oksche A, Beyermann M, et al. Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB. J Pept Sci 2009; 15:479-491.
12. Pollock DM. Dissecting the complex physiology of endothelin: New lessons from genetic models. Hypertension 2010; 56:31-33. A brief history of how transgenic models helped define the physiology of blood pressure regulation by ET-1.
13. Kelland NF, Kuc RE, McLean DL, et al. Endothelial cell-specific ETB receptor knockout: Autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 2010; 88:644-651.
14. Meens MJ, Mattheij NJ, Nelissen J, et al. Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo. Hypertension 2011; 58:99-106. Characterization of the physiological endothelin antagonism of CGRP in vivo and in different vascular beds ex vivo.
15. Meens MJ, Compeer MG, Hackeng TM, et al. Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes. PLoS One 2010; 5:e10917. Confocal images of the vascular wall demonstrates that CGRP but not ETA antagonist can displace ET-1.
16. De Mey JG, Compeer MG, Lemkens P, Meens MJ. ETA-receptor antagonists or allosteric modulators? Trends Pharmacol Sci 2011; 32:345-351. Model for physiological antagonism of CGRP on ET-1-induced vascular contraction.
17. Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010; 299:H1959-H1967.
18. Adner M, Shankley N, Edvinsson L. Evidence that ET-1, but not ET-3 and S6b, ET(A)-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-Activation of ET(B) receptors. Br J Pharmacol 2001; 133:927-935. (Pubitemid 32751803)
19. Schneider MP, Inscho EW, Pollock DM. Attenuated vasoconstrictor responses to endothelin in afferent arterioles during a high-salt diet. Am J Physiol Renal Physiol 2007; 292:F1208-F1214. (Pubitemid 46572439)
20. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92:357-363.
21. Wirth A, Benyo Z, Lukasova M, et al. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med 2008; 14:64-68.
22. 2+ entry channels in endothelin-1-induced contraction of rat aorta using LOE 908 and SK&F 96365. Br J Pharmacol 1999; 127:1388-1398. (Pubitemid 29358939)
23. 2+ store to the plasma membrane. Nature 2005; 437:902-905. (Pubitemid 41486767)
24. 2+ entry. Science 2006; 312:1220-1223. (Pubitemid 43801149)
25. 2+ entry. Proc Natl Acad Sci U S A 2009; 106: 3202-3206.
26. 2+ signaling in vascular smooth muscle cells. J Cell Physiol 2011. doi:10.1002/jcp.22878. [Epub ahead of print] First evidence for a role of STIM1/orai1 in ET-1 induced calcium transients.
27. Seko T, Ito M, Kureishi Y, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003; 92:411-418. (Pubitemid 36298201)
28. 2+ sensitization of vascular smooth muscle contractility. Circ Res 2011; 109:993-1002. This study demonstrates the selective coupling of p63RhoGEF to Gaq/11 during ET-1 stimulation of VSMCs.
29. Wong CM, Cheema AK, Zhang L, Suzuki YJ. Protein carbonylation as a novel mechanism in redox signaling. Circ Res 2008; 102:310-318. (Pubitemid 351271651)
30. Lima VV, Giachini FR, Carneiro FS, et al. O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1. Hypertension 2010; 55:180-188. This study provides evidence that O-GlcNAcylation is increased in response to ET-1. Using pharmacological tools, the authors demonstrate that O-GlcNAcylation mediates the vasoconstrictor effects of ET-1.
31. Lima VV, Giachini FR, Carneiro FS, et al. O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res 2011; 89:614-622. The authors further characterized the importance of O-GlcNAcylation in ET-1-induced signal transduction by studying molecules involved in calcium sensitization.
32. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N- Acetylglucosamine on nucleocytoplasmic proteins. Nature 2007; 446:1017-1022. (Pubitemid 46676063)
33. Lima VV, Giachini FR, Hardy DM, et al. O-GlcNAcylation: A novel pathway contributing to the effects of endothelin in the vasculature. Am J Physiol Regul Integr Comp Physiol 2011; 300:R236-R250.
34. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93:1860-1870. (Pubitemid 26154037)
35. Mortensen LH, Fink GD. Hemodynamic effect of human and rat endothelin administration into conscious rats. Am J Physiol 1990; 258:H362-H368. (Pubitemid 20103157)
36. Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33:753-758. (Pubitemid 29091660)
37. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonistmediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756. (Pubitemid 28135337)
38. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368:703-710. (Pubitemid 24153409)
39. Clouthier DE, Hosoda K, Richardson JA, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998; 125:813-824. (Pubitemid 28142824)
40. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (piebaldlethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994; 79:1267-1276.
41. Gariepy CE, Ohuchi T, Williams SC, et al. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000; 105:925-933. (Pubitemid 30203065)
42. Matsumura Y, Kuro T, Konishi F, et al. Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B) receptor-deficient rats. Br J Pharmacol 2000; 129:1060-1062. (Pubitemid 30153960)
43. Berthiaume N YMD-JP. Contribution of endogenous endothelin-1 and endothelin-A-receptors to the hypertensive state of endothelin-B heterozygous (+/-) knockout mice. J Cardiovasc Pharmacol 2000; 36 (5 Suppl 1):S72-S74.
44. Kisanuki YY, Emoto N, Ohuchi T, et al. Low blood pressure in endothelial cellspecific endothelin 1 knockout mice. Hypertension 2010; 56:121-128. In this study, the first knockout for endothelial ET-1 is presented. A heterozygous null ET-1 model did not present elevated blood pressure in contrast to a previous publication.
45. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99:1380-1389. (Pubitemid 27142776)
46. Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004; 110:2233-2240. (Pubitemid 39372507)
47. Amiri F, Paradis P, Reudelhuber TL, Schiffrin EL. Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens 2008; 26:1102-1109. (Pubitemid 351670501)
48. Amiri F, Ko EA, Javeshghani D, et al. Deleterious combined effects of saltloading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. J Hypertens 2010; 28:1243-1251. This study confirms the role of endothelial ET-1 in high-salt diet-induced increase in BP. Also, this model demonstrates that effects of high-salt diet and ET-1 on the vascular wall are additive.
49. Simeone SM, Li MW, Paradis P, Schiffrin EL. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics 2011; 43:148-160. Characterization of endothelial ET-1-induced change in gene expression using a genomic approach. Demonstration of role of ET-1 in atherosclerosis, and potential link of atherosclerosis with hypertension.
50. Ahn D, Ge Y, Stricklett PK, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004; 114:504-511. (Pubitemid 39572100)
51. Ge Y, Bagnall A, Stricklett PK, et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006; 291:F1274-F1280. (Pubitemid 44889187)
52. Ge Y, Stricklett PK, Hughes AK, et al. Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 2005; 289:F692-F698. (Pubitemid 41324190)
53. Ge Y, Bagnall A, Stricklett PK, et al. Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 2008; 295:F1635-F1640.
54. Bagnall AJ, Kelland NF, Gulliver-Sloan F, et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 2006; 48:286-293. (Pubitemid 44309825)
55. Schiffrin EL, Lariviere R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: Correlation with vascular structure. J Vasc Res 1996; 33:235-248. (Pubitemid 26164473)
56. Schiffrin EL, Lariviere R, Li JS, et al. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25:769-773.
57. Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995; 25:495-500.
58. Sharifi AM, He G, Touyz RM, Schiffrin EL. Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998; 31 (Suppl 1):S309-S312. (Pubitemid 128709936)
59. Spinella F, Rosano L, Del DM, et al. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells. PLoS One 2010; 5:e11241.
60. Balakrishnan SM, Wang HD, Gopalakrishnan V, et al. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 1996; 28:806-809. (Pubitemid 26365522)
61. Yang ZH, Richard V, von SL, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990; 82:188-195. (Pubitemid 20216330)
62. Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosteroneinduced oxidative stress and vascular remodeling. Hypertension 2003; 42:49-55. (Pubitemid 36849598)
63. Stow LR, Gumz ML, Lynch IJ, et al. Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1). J Biol Chem 2009; 284:30087-30096.
64. D'Angelo G, Loria AS, Pollock DM, Pollock JS. Endothelin activation of reactive oxygen species mediates stress-induced pressor response in Dahl salt-sensitive prehypertensive rats. Hypertension 2010; 56:282-289.
65. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4:303-308.
66. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990; 322:205. (Pubitemid 20036412)
67. Haak T, Jungmann E, Felber A, et al. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 1992; 5:161-166.
68. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996; 28:652-655. (Pubitemid 26327964)
69. Hirai Y, Adachi H, Fujiura Y, et al. Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: An epidemiological study. J Hypertens 2004; 22:713-718. (Pubitemid 38543562)
70. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15:57-63. (Pubitemid 27075987)
71. Kumagae S, Adachi H, Jacobs DR Jr., et al. High level of plasma endothelin-1 predicts development of hypertension in normotensive subjects. Am J Hypertens 2010; 23:1103-1107.
72. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338:784-790. (Pubitemid 28135984)
73. Nakov R, Pfarr E, Eberle S. Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15:583-589. (Pubitemid 34734804)
74. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1423-1431.
75. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: Report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824-830.